On October 5, 2026 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported it will present a poster highlighting preclinical data with PoxSTG-EEV, a novel enveloped oncolytic virus designed for systemic delivery, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SITC 2026 will take place November 4 – 8, 2026, in Phoenix, Arizona (USA).
Poster details
Title: "PoxSTG-EEV: a Novel Enveloped Virion–Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery"
• Abstract number: 1050
• Date: November 7, 2026
• Authors: Johann Foloppe, Juliette Kempf, Michèle Klein, Julie Hortelano, Baptiste Moreau, Laurine Gault, Isabelle Farine, Philippe Erbs
The abstract will be available on the SITC (Free SITC Whitepaper) website on November 3, 2026, at 9 a.m. ET
(Press release, Transgene, OCT 5, 2026, View Source [SID1234673180])